iNtRON Biotechnology Inc

iNtRON Biotechnology Inc maintains a strong liquidity position, with cash and equivalents amounting to KRW 44,280,001,021, representing 45.1% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is robust, supported by a current ratio of 13.27, indicating a high ability to meet short-term obligations. However, the company reported a negative free cash flow of KRW -3,213,440,960, driven by capital expenditures of KRW -44,135,290 and a net loss of KRW -375,814,970.

Profitability metrics show a challenging performance, with a return on equity (ROE) of -0.4% and a return on assets (ROA) of -0.38%, both significantly below the industry median for biotechnology firms. The company reported a net loss of KRW -375,814,970 and an operating loss of KRW -1,110,551,240, indicating a lack of operational efficiency and cost control.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in the South Korean biotechnology sector. The company's revenue of KRW 1,910,044,740 is derived from its core biopharmaceutical products, with no material revenue from other segments or international markets.

Looking ahead, the company's revenue outlook is uncertain, with no disclosed growth drivers or new product launches in the near term. The company's operating cash flow of KRW 3,508,489,960 provides some buffer, but the negative free cash flow and operating loss suggest ongoing financial pressures. The company's capital expenditures are minimal, indicating a conservative approach to reinvestment.

The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. The debt-to-equity ratio is 0.0, reflecting a conservative capital structure with no long-term debt. However, the company's negative net income and operating income raise concerns about long-term sustainability and the potential for future dilution if the company requires additional capital.

Recent filings and transcripts do not indicate any material events or strategic shifts. The company has not disclosed any new product approvals, partnerships, or regulatory changes that would significantly impact its financial performance. The absence of recent strategic developments suggests a stable but stagnant business environment.

The company maintains a zero debt-to-equity ratio, ranking in the top quartile of its peer cohort.

Capital expenditure relative to revenue is above the cohort median, suggesting active investment in growth initiatives.

Dilution and liquidity risks are assessed as low, providing a stable capital structure environment for investors.

The company faces high credit risk, signaling potential difficulties in meeting financial obligations or securing favorable financing.

Return on equity is negative at -0.4%, performing below the cohort median of 1.42% for 347 companies.

Cash conversion is -9.34, ranking in the bottom quartile and highlighting severe inefficiency in generating cash from operations.

Revenue KRW 14.01B, −52,2% YoY; Operating income −114,6% YoY.

• ▍Revenue KRW 14.01B, −52,2% YoY
• ▍Operating income −114,6% YoY
• ▍Net income −41,3% YoY
• ▍Free cash flow −38,0% YoY
• ▍Net margin 40.8%

Revenue KRW 29.31B; Operating income KRW 10.08B.

• ▍Revenue KRW 29.31B
• ▍Operating income KRW 10.08B
• ▍Net margin 33.2%